Articles published by AstraZeneca![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
AstraZeneca advances scientific leadership in hematology at ASH 2023
November 29, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![]() ![]()
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
November 17, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
October 16, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![]() ![]() ![]() ![]() ![]()
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
September 11, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![]() ![]()
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|